Synergy Healthcare plc’s Hold Rating Reaffirmed at Jefferies Group (SYR)
Synergy Healthcare plc (LON:SYR)‘s stock had its “hold” rating reissued by stock analysts at Jefferies Group in a report issued on Tuesday. They currently have a GBX 1,646 ($27.31) price objective on the stock. Jefferies Group’s price target would indicate a potential upside of 9.15% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Investec raised their price target on shares of Synergy Healthcare plc from GBX 1,565 ($25.97) to GBX 1,607 ($26.67) in a research note on Thursday, August 14th. They now have a “buy” rating on the stock. Separately, analysts at N+1 Singer raised their price target on shares of Synergy Healthcare plc from GBX 1,258 ($20.88) to GBX 1,283 ($21.29) in a research note on Thursday, July 31st. They now have a “hold” rating on the stock. Finally, analysts at Canaccord Genuity reiterated a “sell” rating on shares of Synergy Healthcare plc in a research note on Wednesday, July 23rd. They now have a GBX 1,218 ($20.21) price target on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of GBX 1,354.14 ($22.47).
Shares of Synergy Healthcare plc (LON:SYR) opened at 1515.00 on Tuesday. Synergy Healthcare plc has a one year low of GBX 991.00 and a one year high of GBX 1522.00. The stock’s 50-day moving average is GBX 1416. and its 200-day moving average is GBX 1349.. The company’s market cap is £892.3 million.
Synergy Health plc and its subsidiaries deliver a range of specialist outsourced services to healthcare providers and other customers concerned with health management.
Receive News & Ratings for Synergy Healthcare plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Healthcare plc and related companies with Analyst Ratings Network's FREE daily email newsletter.